Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy - PubMed (original) (raw)
Randomized Controlled Trial
. 2011 Feb;105(3):409-16.
doi: 10.1017/S0007114510003685. Epub 2010 Sep 24.
Affiliations
- PMID: 20863419
- DOI: 10.1017/S0007114510003685
Randomized Controlled Trial
Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy
Teemu Taipale et al. Br J Nutr. 2011 Feb.
Abstract
The impact of controlled administration of Bifidobacterium animalis subsp. lactis BB-12 (BB-12) on the risk of acute infectious diseases was studied in healthy newborn infants. In this double-blind, placebo-controlled study, 109 newborn 1-month-old infants were assigned randomly to a probiotic group receiving a BB-12-containing tablet (n 55) or to a control group receiving a control tablet (n 54). Test tablets were administered to the infants twice a day (daily dose of BB-12 10 billion colony-forming units) from the age of 1-2 months to 8 months with a novel slow-release pacifier or a spoon. Breastfeeding habits, pacifier use, dietary habits, medications and all signs and symptoms of acute infections were registered. At the age of 8 months, faecal samples were collected for BB-12 determination (quantitative PCR method). The baseline characteristics of the two groups were similar, as was the duration of exclusive breastfeeding. BB-12 was recovered (detection limit log 5) in the faeces of 62% of the infants receiving the BB-12 tablet. The daily duration of pacifier sucking was not associated with the occurrence of acute otitis media. No significant differences between the groups were observed in reported gastrointestinal symptoms, otitis media or use of antibiotics. However, the infants receiving BB-12 were reported to have experienced fewer respiratory infections (65 v. 94%; risk ratio 0·69; 95% CI 0·53, 0·89; P = 0·014) than the control infants. Controlled administration of BB-12 in early childhood may reduce respiratory infections.
Similar articles
- Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in early childhood.
Taipale TJ, Pienihäkkinen K, Isolauri E, Jokela JT, Söderling EM. Taipale TJ, et al. Pediatr Res. 2016 Jan;79(1-1):65-9. doi: 10.1038/pr.2015.174. Epub 2015 Sep 15. Pediatr Res. 2016. PMID: 26372517 Clinical Trial. - Bifidobacterium animalis subsp. lactis BB-12 administration in early childhood: a randomized clinical trial of effects on oral colonization by mutans streptococci and the probiotic.
Taipale T, Pienihäkkinen K, Salminen S, Jokela J, Söderling E. Taipale T, et al. Caries Res. 2012;46(1):69-77. doi: 10.1159/000335567. Epub 2012 Feb 10. Caries Res. 2012. PMID: 22327347 Clinical Trial. - Tetracycline susceptibility of the ingested Lactobacillus acidophilus LaCH-5 and Bifidobacterium animalis subsp. lactis Bb-12 strains during antibiotic/probiotic intervention.
Saarela M, Maukonen J, von Wright A, Vilpponen-Salmela T, Patterson AJ, Scott KP, Hämynen H, Mättö J. Saarela M, et al. Int J Antimicrob Agents. 2007 Mar;29(3):271-80. doi: 10.1016/j.ijantimicag.2006.09.020. Epub 2007 Jan 5. Int J Antimicrob Agents. 2007. PMID: 17207972 - Health benefits of Lactobacillus rhamnosus GG and Bifidobacterium animalis subspecies lactis BB-12 in children.
Szajewska H, Hojsak I. Szajewska H, et al. Postgrad Med. 2020 Jun;132(5):441-451. doi: 10.1080/00325481.2020.1731214. Epub 2020 Feb 26. Postgrad Med. 2020. PMID: 32059116 Review. - Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention.
Halken S. Halken S. Pediatr Allergy Immunol. 2004 Jun;15 Suppl 16:4-5, 9-32. doi: 10.1111/j.1399-3038.2004.0148b.x. Pediatr Allergy Immunol. 2004. PMID: 15125698 Review.
Cited by
- The Respiratory Microbiome in Paediatric Chronic Wet Cough: What Is Known and Future Directions.
Atto B, Anteneh Y, Bialasiewicz S, Binks MJ, Hashemi M, Hill J, Thornton RB, Westaway J, Marsh RL. Atto B, et al. J Clin Med. 2023 Dec 28;13(1):171. doi: 10.3390/jcm13010171. J Clin Med. 2023. PMID: 38202177 Free PMC article. Review. - Role of multi-strain probiotics in preventing severity and frequency of recurrent respiratory tract infections in children.
Khan Laghari I, Nawaz T, Mustafa S, Jamali AA, Fatima S. Khan Laghari I, et al. BMC Pediatr. 2023 Oct 11;23(1):505. doi: 10.1186/s12887-023-04338-x. BMC Pediatr. 2023. PMID: 37817096 Free PMC article. - Effect of probiotics as an immune modulator for the management of COVID-19.
Ray M, Manjunath A, Halami PM. Ray M, et al. Arch Microbiol. 2023 Apr 9;205(5):182. doi: 10.1007/s00203-023-03504-0. Arch Microbiol. 2023. PMID: 37031431 Free PMC article. - Potential probiotics for regulation of the gut-lung axis to prevent or alleviate influenza in vulnerable populations.
Wang YH, Limaye A, Liu JR, Wu TN. Wang YH, et al. J Tradit Complement Med. 2022 Aug 18;13(2):161-169. doi: 10.1016/j.jtcme.2022.08.004. eCollection 2023 Mar. J Tradit Complement Med. 2022. PMID: 36970463 Free PMC article. Review. - The Antimicrobial Effect of Various Single-Strain and Multi-Strain Probiotics, Dietary Supplements or Other Beneficial Microbes against Common Clinical Wound Pathogens.
Fijan S, Kocbek P, Steyer A, Vodičar PM, Strauss M. Fijan S, et al. Microorganisms. 2022 Dec 19;10(12):2518. doi: 10.3390/microorganisms10122518. Microorganisms. 2022. PMID: 36557771 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources